NOVELOS INITIATES OVARIAN CANCER TREATMENT TRIAL

Novelos Therapeutics announced that Partners Cancer Care has enrolled the first patient in a Phase II trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients.

The primary objective of this open-label, single-arm trial will be to determine the tumor response rate in women with platinum-resistant ovarian cancer after treatment with NOV-002 and carboplatin. Up to 25 women will be enrolled in the trial, and they may receive up to six cycles of treatment. Interim results are expected in early 2007.